XML 112 R78.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($) shares in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Jan. 31, 2019 | Jun. 30, 2018 | Mar. 31, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2018 | Jun. 05, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Research and development |  | $ 981.0 |  | $ 796.2 | $ 1,477.7 | $ 1,219.6 |  |
Inventory charges |  | 421.0 |  | 366.2 | 867.0 | 750.8 |  |
Other revenues |  | (3,356.5) |  | (3,078.4) | (6,487.6) | (5,889.1) |  |
Collaboration profit (loss) sharing |  | 39.2 |  | 26.5 | 81.7 | 47.3 |  |
ZINBRYTA |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Research and development |  |  | $ 12.8 |  |  |  |  |
Inventory charges |  |  | $ 2.4 |  |  |  |  |
Other revenues |  | 0.0 |  | (16.1) | (1.4) | (26.8) |  |
OCREVUS |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalty operating profit threshold for highest royalty rate percentage |  | 900.0 |  |  | $ 900.0 |  |  |
Reduction in royalty rate |  |  |  |  | 50.00% |  |  |
Period of collaboration agreement |  |  |  |  | 11 years |  |  |
Revenues from anti-CD20 therapeutic programs |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Other revenues |  | $ (490.4) |  | (397.1) | $ (933.6) | (737.7) |  |
Ionis Pharmaceuticals |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Term of collaboration agreement |  | 10 years |  |  |  |  |  |
Total payment to enter collaboration agreement |  |  |  |  |  |  |  | $ 1,000.0
Upfront payment for collaboration agreement |  |  |  |  |  |  |  | $ 375.0
Investment in common stock, shares purchased |  |  |  |  |  |  |  | 11.5
Purchase of common stock |  |  |  |  |  |  |  | $ 625.0
Prepaid research and development services |  | $ 50.9 |  |  | $ 50.9 |  |  |
Research and development |  | 324.1 |  |  |  |  |  |
Investment in common stock, value |  |  |  |  |  |  |  | 462.9
Premium on purchase of common stock |  |  |  |  |  |  |  | $ 162.1
AbbVie |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Biogen share of co-promotion profits or losses |  |  |  |  | 50.00% |  |  |
Eisai | E2609 and BAN2401 |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Expense incurred by the collaboration |  | 54.6 |  | 29.5 | $ 111.1 | 66.7 |  |
Expense reflected within statements of income |  | 27.3 |  | 14.7 | 55.5 | 33.3 |  |
Genentech |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration expenses in dispute |  |  |  |  | 120.0 |  |  |
Reimbursement of aducanumab | Eisai |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Percentage of future development costs related to Eisai | 45.00% |  |  |  |  |  | 15.00% |
U.S. | ZINBRYTA |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Other revenues |  | 0.0 |  | 0.0 | 0.0 | 0.0 |  |
E.U. and Canada | AbbVie |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Collaboration profit (loss) sharing |  | 0.5 |  |  | 1.8 | 1.3 |  |
Rest of world | ZINBRYTA |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Other revenues |  | 0.0 |  | (16.1) | $ (1.4) | (26.8) |  |
Rest of world | OCREVUS |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalties percentage to be received on sale of product |  |  |  |  | 3.00% |  |  |
Minimum | OCREVUS |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalties percentage to be received on sale of product |  |  |  |  | 13.50% |  |  |
Minimum | Ionis Pharmaceuticals |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of milestones |  |  |  |  | $ 125.0 |  |  |
Maximum | OCREVUS |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Royalties percentage to be received on sale of product |  |  |  |  | 24.00% |  |  |
Maximum | Ionis Pharmaceuticals |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Estimated additional payments upon achievement of milestones |  |  |  |  | $ 270.0 |  |  |
Research and development | Eisai | Aducanumab |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Expense incurred by the collaboration |  | 76.5 |  | 74.6 | 140.0 | 128.9 |  |
Expense reflected within statements of income |  | 65.0 |  | 74.6 | 128.5 | 128.9 |  |
Selling, general and administrative | Eisai | Aducanumab |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Expense incurred by the collaboration |  | 14.0 |  | 4.8 | 21.2 | 9.8 |  |
Expense reflected within statements of income |  | 9.2 |  | 4.8 | 13.9 | 9.8 |  |
AbbVie | Collaborative arrangement |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Other revenues |  | (2.5) |  | (3.9) | (7.2) | (9.8) |  |
AbbVie | U.S. | Collaborative arrangement |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Other revenues |  | (2.5) |  | (3.9) | (7.2) | (9.8) |  |
Genentech |  |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses |  | 359.0 |  | 347.5 | 708.6 | 671.0 |  |
Other revenues from anti-CD20 therapeutic programs |  | $ 131.4 |  | $ 49.6 | $ 225.0 | $ 66.7 |  |

X
- Definition Biogen share of co-promotion profits or losses + References No definition available. + Details
Name: | biib_Biogenshareofcopromotionprofitsorlosses
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration expenses in dispute + References No definition available. + Details
Name: | biib_Collaborationexpensesindispute
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration profit (loss) sharing + References No definition available. + Details
Name: | biib_Collaborationprofitlosssharing
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Estimated additional payments upon achievement of development and commercial milestones. + References No definition available. + Details
Name: | biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expense incurred by the collaboration + References No definition available. + Details
Name: | biib_Expenseincurredbythecollaboration
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expense reflected within statements of income + References No definition available. + Details
Name: | biib_Expensereflectedwithinstatementsofincome
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Investment in common stock, shares purchased + References No definition available. + Details
Name: | biib_Investmentincommonstocksharespurchased
Namespace Prefix: | biib_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Investment in common stock, value + References No definition available. + Details
Name: | biib_Investmentincommonstockvalue
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus. + References No definition available. + Details
Name: | biib_OtherrevenuesfromantiCD20therapeuticprograms
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of future development costs related to Eisai + References No definition available. + Details
Name: | biib_PercentageoffuturedevelopmentcostsrelatedtoEisai
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period Of Collaboration Agreement + References No definition available. + Details
Name: | biib_PeriodOfCollaborationAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Premium on purchase of common stock + References No definition available. + Details
Name: | biib_Premiumonpurchaseofcommonstock
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Purchase of common stock + References No definition available. + Details
Name: | biib_Purchaseofcommonstock
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Reduction in royalty rate + References No definition available. + Details
Name: | biib_Reductioninroyaltyrate
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalties Percentage To Be Received On Sale Of Product + References No definition available. + Details
Name: | biib_RoyaltiesPercentageToBeReceivedOnSaleOfProduct
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty operating profit threshold for highest royalty rate percentage + References No definition available. + Details
Name: | biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Share of co promotion profits. + References No definition available. + Details
Name: | biib_ShareOfCoPromotionProfits
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Term of collaboration agreement + References No definition available. + Details
Name: | biib_Termofcollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total payment to enter collaboration agreement + References No definition available. + Details
Name: | biib_Totalpaymenttoentercollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payment for collaboration agreement + References No definition available. + Details
Name: | biib_Upfrontpaymentforcollaborationagreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets. + References No definition available. + Details
Name: | us-gaap_PrepaidExpenseAndOtherAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=biib_ZINBRYTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_OCREVUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_EisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_E2609andBAN2401Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=biib_RocheGroupGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=biib_RestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_AducanumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=biib_AbbVieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=biib_RocheGroupGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |